In a joint statement that underscores growing concerns about the misuse of prescription drugs, the Medicines Control Authority of Zimbabwe (MCAZ) and the Health Professions Authority of Zimbabwe (HPA) have sounded an alarm over the illegal sale and use of Ozempic, an injectable diabetes medication now being misused as a quick-fix weight-loss jab.
Known colloquially as the “skinny jab,” Ozempic’s emergence as a trendy weight-loss tool on social media has ignited both curiosity and controversy. Originally intended for managing type 2 diabetes under the strict supervision of licensed medical professionals, the drug is now increasingly available through online marketplaces, unlicensed premises, and informal networks that lack any regulatory oversight.
“It’s not just illegal, it’s dangerous,” warned MCAZ Director-General Mr. Richard T. Rukwata in the release. “Self-medicating with Ozempic for weight loss can have serious and potentially life-threatening consequences.” His warning highlights the dual threat posed by the drug’s off-label use: a risk to individual health and a challenge to the integrity of Zimbabwe’s healthcare system.
The health authorities’ message is clear: Ozempic, like all prescription medicines, is not a casual commodity. Its distribution and use are governed by stringent laws, specifically the Medicines and Allied Substances Control Act and related statutory instruments, that require prescriptions from qualified, licensed professionals. Selling or using Ozempic outside of these legal parameters, the authorities stress, is not only an offense but also a direct threat to public health.
The statement pointed to disturbing trends: unregistered sellers offering Ozempic on social media, bypassing all quality controls, and putting lives at risk. Without proper medical supervision, users can experience severe side effects including hypoglycemia, pancreatitis, and even life-threatening complications.
“We want to remind the public that only qualified, licensed professionals can diagnose and prescribe medication,” emphasized HPA Secretary General Mrs. Clotilda Chimbwanda. “Anything else is a violation of health regulations and a risk to every patient.”
This crackdown is more than a regulatory exercise, it’s a battle to uphold public trust in Zimbabwe’s healthcare system. The illegal trade in prescription drugs undermines efforts to ensure that medicines are safe, effective, and of good quality. It also threatens to widen the already problematic gap between public health priorities and market-driven, profit-oriented sales tactics.
For communities already grappling with challenges like limited access to health services and economic hardships, the allure of a quick weight-loss solution is understandable, but authorities caution that desperation should not override caution. “Consumers should be suspicious of anyone offering prescription medicine without a prescription,” Rukwata added.
Looking ahead, MCAZ and HPA are urging the public to verify the legitimacy of health practitioners and facilities. This includes checking for valid practicing certificates and proper licensing, steps that could mean the difference between safe treatment and avoidable tragedy.
As Zimbabwe charts its path towards an upper-middle-income economy under Vision 2030, the fight against the illicit trade in medicines like Ozempic reflects a broader struggle: balancing public health and safety in an era of digital marketplaces and growing consumer demand for quick fixes.
In the end, the message from authorities is unwavering: when it comes to your health, shortcuts can be fatal. Only trust licensed professionals, and say no to illegal sales, because safety, more than ever, is not negotiable.
